Phytotherapy for Benign Prostatic Hyperplasia

  title={Phytotherapy for Benign Prostatic Hyperplasia},
  author={Aryeh Y Keehn and Jacob Taylor and Franklin C. Lowe},
  journal={Current Urology Reports},
IntroductionThe use of complementary and alternative medications for symptomatic benign prostatic hyperplasia is a lucrative business in the USA with revenues reaching close to US$6.4 billion in sales for the 2014 fiscal year. Yet, despite its popularity, the evidence supporting the continued use of phytotherapy for symptomatic benign prostatic hyperplasia (BPH) is questionable and a topic worth investigation given its wide spread use.MethodsA comprehensive literature search utilizing Medline… 
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
The effects of naftopidil for the treatment of LUTS associated with BPH and tamsulosin are evaluated, with the certainty of evidence as moderate for urological symptom score and low for the other outcomes.
Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
The effects of silodosin for the treatment of LUTS in men with benign prostatic hyperplasia and the quality of evidence was evaluated according to the Cochrane Handbook for Systematic Reviews of Interventions.
Contemporary use of phytotherapy in patients with lower urinary tract symptoms due to benign prostatic hyperplasia: results from the EVOLUTION European registry
Low heterogeneous prescribing rates for phytotherapy were reported in both PUP and c-PTP cohorts over the 24-month FU, and healthcare practitioners should prescribe them with caution until higher quality evidence and guideline recommendations supporting its use are available.
Potential Therapeutic Effects of Underground Parts of Kalanchoe gastonis-bonnieri on Benign Prostatic Hyperplasia
There is a potential therapeutic use for KGB in BPH, which could improve the clinical management of the disease, and the findings show that the extract of the KGB underground parts stimulates important changes in the BPH cells, modulating crucial processes such as proliferation, viability, and apoptosis.
Comparison of Tamsulosin Plus Serenoa Repens with Tamsulosin in the Treatment of Benign Prostatic Hyperplasia in Korean Men: 1-Year Randomized Open Label Study
The combination treatment of Serenoa repens and tamsulosin was shown to be more effective than tamsULosin monotherapy in reducing storage symptoms in BPH patients after 6 months and up to 12 months of treatment.
Inflammatory pathway employed by Red Maca to treat induced benign prostatic hyperplasia in rats
Assessment of the inflammatory effect of RM and finasteride in rats with testosterone enanthate‐induced BPH suggested thatfinasteride acts on Th2 response by increasing IL4 in prostate, while Red Maca acts onTh1 response mediated by INFg.
Chemical profiles of the active fraction from Prinsepia utilis Royle leaves and its anti-benign prostatic hyperplasia evaluation in animal models
Background The Prinsepia utilis Royle leaves ( P. utilis ) is a folk herb used for benign prostatic hyperplasia (BPH) control by ethnic minorities for centuries in China with rich in resources. Our
Pao Pereira Extract Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by inhibiting 5α-Reductase
It is suggested that Pao extract may be a promising and relative safe agent for BPH because it suppresses testosterone-induced BPH development through inhibiting AR activity and expression.
Isosamidin, an extract of Peucedanum japonicum, inhibits phenylephrine‐mediated contractions of the human prostate in vitro
Whether isosamidin inhibits agonist‐stimulated contractions in isolated human bladder and prostate tissue strips in vitro is examined and may have pharmacological potency in the treatment of male patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.


Complementary and alternative medications for benign prostatic hyperplasia.
Based on the available literature, there is no evidence that phytotherapy significantly improves symptoms of BPH against placebo, despite being largely safe for ingestion.
Serenoa repens for benign prostatic hyperplasia.
The main outcome measure for comparing the effectiveness of Serenoa repens with placebo or other interventions was the change in urologic symptom-scale scores, and secondary outcomes included changes in nocturia and urodynamic measures.
Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review.
The evidence suggests that S repens improves urologic symptoms and flow measures and was associated with fewer adverse treatment events in men with symptomatic benign prostatic hyperplasia.
WITHDRAWN: Tamsulosin for benign prostatic hyperplasia.
Tamsulosin was as effective as other alpha antagonists and the phytotherapeutic agent Permixon® in improving symptoms and flow rates though the doses of all alpha-antagonists studied may not have been optimal.
Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action.
  • A. Buck
  • Medicine, Biology
    The Journal of urology
  • 2004
It would appear that the n-hexane lipidosterolic extract of Serenoa repens, namely Permixon, is a product that has uniquely been subjected to more scientific investigation than any other such preparation.
Beta-sitosterols for benign prostatic hyperplasia.
The evidence suggests non-glucosidic B-sitosterols improve urinary symptoms and flow measures and their long term effectiveness, safety and ability to prevent BPH complications are not known.
Role of growth factors in benign prostatic hyperplasia.
A hypothesis of the mechanism of action of these growth factors in the developmental of BPH is presented and targeting growth factors potentially represents a direct therapeutic approach to the regulation of abnormal enlargement of the prostate and the amelioration of other symptoms associated with BPH.
BPH: epidemiology and comorbidities.
  • K. McVary
  • Medicine
    The American journal of managed care
  • 2006
Although effective treatments for LUTS/BPH are available, this condition often occurs in the context of common, age-related comorbidities such as cardiovascular disease, hypertension, and erectile dysfunction.